To thoroughly implement the strategic deployment of expanding high-level opening-up as outlined in the Third Plenary Session of the 20th CPC Central Committee, and to actively promote orderly opening-up in the pharmaceutical and healthcare sectors, the International Cooperation Center of the National Development and Reform Commission (NDRC) recently launched a special research project on new areas of medical and pharmaceutical openness. During the visit, the research team visited Deep Harbour Cell Valley, where they engaged in in-depth discussions with senior executives of local companies on cutting-edge industry topics. 1. A high-caliber research team focused on cutting-edge industry issues. The research was led by Qiu Aijun, Deputy Director of the International Cooperation Center of the National Development and Reform Commission, with members including Li Huaxiang (Deputy Director and Associate Researcher of the Consultation and Research Department), Guo Fangcui (Assistant Researcher of the Low-altitude Economy Research Office), and Shan Shiyao (staff member of the Major Events Department). Accompanying them were Zhang Fei (Deputy Director and Associate Researcher of the Foreign Investment Institute at the Academy of International Trade and Economic Cooperation, Ministry of Commerce) and Zhao Yue (graduate student from Beijing Technology and Business University), who participated as members of the research team. The research team, grounded in national macro-strategies, focuses on the new open landscape of pharmaceutical and healthcare sectors, providing research support for policy-making and driving the industry's sustainable and healthy development. 2. Deep Harbour Cell Valley hosted the delegation with warm hospitality, showcasing its corporate strength. The company placed high importance on this research visit, with senior executives including Chairman Professor Shi Yuanyuan and Chief Medical Officer Professor David Kin Jin personally receiving the delegation. During the symposium, Professor Shi elaborated on the company's development history, strategic layout, and future plans, highlighting its organizational structure, service modules, core products, and technological advantages in cell therapy and health management. These presentations vividly demonstrated the company's research capabilities and growth potential. 3. In-depth discussions to jointly advance the pharmaceutical and healthcare industry. During the subsequent symposium, both parties engaged in thorough, pragmatic, and candid exchanges on hot topics in the newly liberalized pharmaceutical and healthcare sectors. The discussions covered critical national concerns, including the implementation and execution of new opening-up policies. This interaction not only deepened the research team's understanding of enterprises' current status and needs but also provided first-hand materials and valuable references for future policy formulation. The research initiative by the International Cooperation Center of the National Development and Reform Commission not only demonstrates strong focus on new sectors in the pharmaceutical and healthcare industries, but also establishes a solid foundation for aligning policies with industrial realities and supporting the real economy. Deep Harbour Cell Valley will seize this opportunity to uphold its open and innovative spirit, actively engage in government collaborations, and contribute to building a globally competitive ecosystem for cell therapy and health management. With the joint efforts of government and industry, the sector is poised for greater prosperity, making more substantial contributions to public health and well-being.